Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2009. The report serves as a notification to the market regarding the Company's issued share capital and total voting rights as of April 30, 2009, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
| Metric | Value |
|---|---|
| Issued Ordinary Shares (25p each) | 5,662,573,977 |
| Treasury Shares | 474,194,158 |
| Total Voting Rights | 5,188,379,819 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. No comparative data for previous periods is included in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share capital and does not contain operational commentary or forward-looking statements.
Investor Verification Checklist
- Verify the total number of voting rights (5,188,379,819) for compliance with Financial Services Authority Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (474,194,158) to calculate the net outstanding share count.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and profit metrics.